Haemophilia B with anti factor IX – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 10:34:35 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Haemophilia B with anti factor IX – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study on How Concizumab Works for Patients with Hemophilia A or B with Inhibitors https://clinicaltrials.eu/trial/study-on-how-concizumab-works-for-patients-with-hemophilia-a-or-b-with-inhibitors/ Wed, 29 Apr 2026 14:57:21 +0000 https://clinicaltrials.eu/trial/study-on-how-concizumab-works-for-patients-with-hemophilia-a-or-b-with-inhibitors/ This clinical trial is focused on studying the effects of a medication called concizumab in people with hemophilia A or hemophilia B who have developed inhibitors. Hemophilia is a condition where the blood does not clot properly, leading to excessive bleeding. Inhibitors are antibodies that can develop in some patients, making standard treatments less effective. The medication being tested, concizumab, is given as a solution for injection using a pen-injector device.

The purpose of the study is to see how well concizumab works in reducing the number of bleeding episodes compared to no regular preventive treatment. Participants will be divided into groups, with some receiving concizumab and others receiving their usual on-demand treatment. The study will last for several months, during which participants will receive regular injections of concizumab and be monitored for any changes in their bleeding patterns.

Throughout the study, researchers will collect information on the number of bleeding episodes, any side effects, and how the participants feel physically. This information will help determine if concizumab is a safe and effective treatment option for people with hemophilia A or B with inhibitors. The study aims to provide valuable insights into managing this condition and improving the quality of life for those affected.

]]> Study on the Safety and Effectiveness of SerpinPC for Patients with Hemophilia B with Inhibitors https://clinicaltrials.eu/trial/study-on-the-safety-and-effectiveness-of-serpinpc-for-patients-with-hemophilia-b-with-inhibitors/ Wed, 29 Apr 2026 14:23:39 +0000 https://clinicaltrials.eu/trial/study-on-the-safety-and-effectiveness-of-serpinpc-for-patients-with-hemophilia-b-with-inhibitors/ This clinical trial is focused on studying a condition known as Hemophilia B, which is a genetic disorder that affects the blood’s ability to clot properly. People with this condition can experience excessive bleeding even from minor injuries. The study is testing a new treatment called SerpinPC, which is a modified form of a protein known as human alpha-1 proteinase inhibitor. This treatment is given as a solution for injection under the skin.

The purpose of the study is to evaluate how effective and safe SerpinPC is for people with Hemophilia B who have developed inhibitors. Inhibitors are antibodies that can make standard treatments less effective. Participants in the study will receive regular injections of SerpinPC and will be monitored over a period of time to see how well the treatment works in reducing bleeding episodes. Some participants may receive a placebo, which is a substance with no active medication, to compare the effects.

The study will last for a total of 48 weeks, during which participants will be closely observed for any changes in their condition and any side effects they might experience. The main focus will be on the number of bleeding episodes that require treatment, as well as the overall health and quality of life of the participants. This trial aims to provide valuable information on whether SerpinPC can be a beneficial treatment option for those living with Hemophilia B with inhibitors.

]]>